Tetsuya Isaka1,2, Hiroyuki Ito3, Haruhiko Nakayama1, Tomoyuki Yokose4, Kayoko Katayama5, Kouzo Yamada6, Munetaka Masuda2. 1. Department of Thoracic Surgery, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi, Yokohama, Kanagawa, 241-8515, Japan. 2. Department of Surgery, Yokohama City University, 3-9 Fukuura, Kanazawa, Yokohama, Kanagawa, 236-0004, Japan. 3. Department of Thoracic Surgery, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi, Yokohama, Kanagawa, 241-8515, Japan. h-ito@kcch.jp. 4. Department of Pathology, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi, Yokohama, Kanagawa, 241-8515, Japan. 5. Kanagawa Cancer Center Research Institute Cancer Prevention and Control Division, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi, Yokohama, Kanagawa, 241-8515, Japan. 6. Department of Thoracic Oncology, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi, Yokohama, Kanagawa, 241-8515, Japan.
Abstract
OBJECTIVE: This study aimed to retrospectively evaluate the efficacy of platinum-based adjuvant chemotherapy (PBAC) for patients with pathological II/III pulmonary adenocarcinoma after curative resection based on epidermal growth factor receptor (EGFR) mutation status using propensity score matching (PSM) analysis. METHODS: Among the 304 patients who underwent curative resection of the lung for pathological II/III pulmonary adenocarcinoma from 2002 to 2016 at the Kanagawa Cancer Center, 176 and 128 patients were wild-type EGFR (Wt) and mutant EGFR (Mt), respectively. Seventy-one Wt patients (40.3%) and 60 Mt patients (46.9%) received PBAC. The prognoses of Wt and Mt patients who did and did not receive PBAC were compared using PSM analysis to reduce bias. RESULTS: The overall survival (OS) of both Wt and Mt patients who received PBAC was significantly better than that of patients who did not receive PBAC before PSM. By multivariate analysis, PBAC was an independent prognostic factor for OS among Wt patients, as were age, carcinoembryonic antigen (CEA) level, pleural invasion, and lymph node metastasis. Although age and CEA level were independent factors for OS among Mt patients, PBAC was not a prognostic factor. After PSM, Wt patients who received PBAC had better OS than those who did not, although Mt patients who did and did not receive PBAC had no difference in OS. CONCLUSIONS: PBAC was associated with favorable prognosis after curative resection among Wt patients, but not among Mt patients. PBAC might not be necessary for Mt patients with pathological stage II/III pulmonary adenocarcinoma.
OBJECTIVE: This study aimed to retrospectively evaluate the efficacy of platinum-based adjuvant chemotherapy (PBAC) for patients with pathological II/III pulmonary adenocarcinoma after curative resection based on epidermal growth factor receptor (EGFR) mutation status using propensity score matching (PSM) analysis. METHODS: Among the 304 patients who underwent curative resection of the lung for pathological II/III pulmonary adenocarcinoma from 2002 to 2016 at the Kanagawa Cancer Center, 176 and 128 patients were wild-type EGFR (Wt) and mutant EGFR (Mt), respectively. Seventy-one Wt patients (40.3%) and 60 Mt patients (46.9%) received PBAC. The prognoses of Wt and Mt patients who did and did not receive PBAC were compared using PSM analysis to reduce bias. RESULTS: The overall survival (OS) of both Wt and Mt patients who received PBAC was significantly better than that of patients who did not receive PBAC before PSM. By multivariate analysis, PBAC was an independent prognostic factor for OS among Wt patients, as were age, carcinoembryonic antigen (CEA) level, pleural invasion, and lymph node metastasis. Although age and CEA level were independent factors for OS among Mt patients, PBAC was not a prognostic factor. After PSM, Wt patients who received PBAC had better OS than those who did not, although Mt patients who did and did not receive PBAC had no difference in OS. CONCLUSIONS: PBAC was associated with favorable prognosis after curative resection among Wt patients, but not among Mt patients. PBAC might not be necessary for Mt patients with pathological stage II/III pulmonary adenocarcinoma.
Authors: Timothy Winton; Robert Livingston; David Johnson; James Rigas; Michael Johnston; Charles Butts; Yvon Cormier; Glenwood Goss; Richard Inculet; Eric Vallieres; Willard Fry; Drew Bethune; Joseph Ayoub; Keyue Ding; Lesley Seymour; Barbara Graham; Ming-Sound Tsao; David Gandara; Kenneth Kesler; Todd Demmy; Frances Shepherd Journal: N Engl J Med Date: 2005-06-23 Impact factor: 91.245
Authors: Ming-Sound Tsao; Sophie Marguet; Gwénaël Le Teuff; Sylvie Lantuejoul; Frances A Shepherd; Lesley Seymour; Robert Kratzke; Stephen L Graziano; Helmut H Popper; Rafael Rosell; Jean-Yves Douillard; Thierry Le-Chevalier; Jean-Pierre Pignon; Jean-Charles Soria; Elisabeth M Brambilla Journal: J Clin Oncol Date: 2015-04-27 Impact factor: 44.544
Authors: Glenwood D Goss; Chris O'Callaghan; Ian Lorimer; Ming-Sound Tsao; Gregory A Masters; James Jett; Martin J Edelman; Rogerio Lilenbaum; Hak Choy; Fadlo Khuri; Katherine Pisters; David Gandara; Kemp Kernstine; Charles Butts; Jonathan Noble; Thomas A Hensing; Kendrith Rowland; Joan Schiller; Keyue Ding; Frances A Shepherd Journal: J Clin Oncol Date: 2013-08-26 Impact factor: 44.544
Authors: Frances A Shepherd; Caroline Domerg; Pierre Hainaut; Pasi A Jänne; Jean-Pierre Pignon; Stephen Graziano; Jean-Yves Douillard; Elizabeth Brambilla; Thierry Le Chevalier; Lesley Seymour; Abderrahmane Bourredjem; Gwénaël Le Teuff; Robert Pirker; Martin Filipits; Rafael Rosell; Robert Kratzke; Bizhan Bandarchi; Xiaoli Ma; Marzia Capelletti; Jean-Charles Soria; Ming-Sound Tsao Journal: J Clin Oncol Date: 2013-04-29 Impact factor: 44.544